FDA Investigator Sri Ramakrishnaiah Yellela, PhD
Sri Ramakrishnaiah Yellela, PhD has conducted inspections on 7 sites in 4 countries as of 15 Dec 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
7
Last Inspection Date:
15 Dec 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
United States of America,
India,
Italy,
Germany
FDA Investigators that have inspected at least one site in common with Sri Ramakrishnaiah Yellela, PhD:
Angela E Glenn,
Atul J Agrawal,
Azza Talaat,
Bei Y He,
Carrie A Hughes,
Charles L Zhou,
Christopher M Jenner,
Constantin Y Philopoulos,
Cynthia M Goudeau,
David A Paterson,
David J Eide,
Derrionna M Epps,
Dipesh K Shah,
Dustin K Hampton,
Emest F Bizjak,
Eric C Nielsen,
Eric M Padgett,
Erika V Butler,
Gene R Gunn,
Gloria J Champagne,
Jacob G Lutz,
James I Giefer,
Javier O Vega,
Jeffrey A Sommers,
Jeffrey P Raimondi,
Jill J Tillman,
Junho Pak,
Karen C Daugherty,
Karen M Montgomery (KMM),
Linda F Murphy,
Logan T Williams,
Matthew B Casale,
Matthew M Schuckmann,
Matthew Schuckman,
Meisha Waters,
Michael C Zubelewicz,
Michael L Casner,
Michele L Obert,
Michele Perry Williams,
Monica E Murie,
Nadeem I Chaudhry,
Rajiv R Srivastava,
Rebecca Rodriguez,
Robert J Ham,
Robert M Barbosa,
Ruben C Ayala, PharmD,
Saied A Asbagh,
Sandra A Hughes,
Scott N Lim,
Srinivas R Chennamaneni, PhD,
Steven P Donald,
Tara L Greene,
Tara L King,
Unnee Ranjan,
Veronica Fuentes, MS,
Victoria P Quadrini,
Vikas Moolchandani,
Xiaohan Cai, PhD,
Yiyue Zhang (nmi), PhD,
Youmin Wang,
Zachary L Miller,
Zhongren Wu
Sri Ramakrishnaiah Yellela, PhD's Documents
Publish Date | Document Type | Title |
---|---|---|
November, 2018 | EIR | Annora Pharma Private Limited - EIR, 2018-11-10 |
February, 2020 | FDA 483 | S&B Pharma LLC DBA Alkem Laboratories - Form 483, 2020-02-06 |
September, 2023 | EIR | Curia Indiana, LLC - EIR, 2023-10-04 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more